Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the fact that an estimated 50 million people worldwide suffer from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). The company’s approach concentrates on correcting the cellular pathologies driven by misfolded proteins, the altered biology or phenotypes driving these diseases.
Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS. Targeting the underlying protein pathology of neurodegenerative diseases allows the company to discover therapies that may modify the root cause of these rather than only addressing their symptoms.
If you are interested in a career at Yumanity Therapeutics, please contact us at careers@yumanity.com.
Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS. Targeting the underlying protein pathology of neurodegenerative diseases allows the company to discover therapies that may modify the root cause of these rather than only addressing their symptoms.
If you are interested in a career at Yumanity Therapeutics, please contact us at careers@yumanity.com.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $10M
Founded date: 2006
Investors 4
| Date | Name | Website |
| - | New Enterp... | nea.com |
| - | Avoro Capi... | avorocapit... |
| - | F-Prime Ca... | fprimecapi... |
| - | Eight Road... | eightroads... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.08.2014 | - | $10M | - |
Mentions in press and media 6
| Date | Title | Description |
| 24.08.2020 | PROTEOSTASIS THERAPEUTICS, INC. Proteostasis Therapeutics : Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement | BOSTON, Aug. 24, 2020 /PRNewswire/ -- Yumanity Therapeutics and Proteostasis Therapeutics, Inc. (Nasdaq: PTI) today announced that the companies have entered into a definitive merger agreement. The combined company, operating under the name... |
| 17.12.2019 | Versus Vertex, Proteostasis' triplet CF data fall short, wilting stock | It’s too little, too late for little Proteostasis Therapeutics. The Boston drug developer that is looking to take on Vertex Pharmaceuticals — and the company’s entrenched slate of cystic fibrosis medicines — report... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 08.09.2015 | Proteostasis Therapeutics, Inc. Raises $37 Million in Crossover Financing | - |
| 15.08.2014 | The well-capitalized Proteostasis Therapeutics raising $10M for protein-folding tech | This is a relatively small raise for the well-capitalized company – it has a good deal of investment from outside pharma partners, and debuted on the biotech scene in 2008 with an impressive $45 million venture financing from HealthCare Ven... |
| - | The well-capitalized Proteostasis Therapeutics raising $10M for protein-folding tech | The concept of using protein homeostasis – or proteostasis – as a platform for drug development is a rather new one, but it makes a good amount of sense: Maintaining a proper balance of protein production in the body is critical to a person... |